Assembly Biosciences Announces Proposed Public Offering of Common Stock
December 11 2019 - 4:03PM
Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today
announced that it intends to offer and sell, subject to market and
other conditions, shares of its common stock in an underwritten
public offering. Assembly also intends to grant the underwriters a
30-day option to purchase up to an additional 15% of the shares of
common stock offered in the public offering. There can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering. All of the shares
in the proposed offering are to be sold by Assembly.
Jefferies LLC, SVB Leerink LLC and William Blair & Company,
L.L.C. are acting as joint bookrunning managers for the
offering.
The securities described above are being offered pursuant to a
shelf registration statement (File No. 333-222366), which was
declared effective by the U.S. Securities and Exchange Commission
(“SEC”) on January 10, 2018. The offering can be made only by means
of a prospectus supplement and accompanying prospectus. Copies of
the preliminary prospectus supplement and the accompanying
prospectus may be obtained at the SEC's website at www.sec.gov, or
by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 821-7388, or by email at prospectus
department@jefferies.com; SVB Leerink LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, by
telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, by telephone at (800) 621-0687, or by email at
prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About Assembly Biosciences Assembly
Biosciences, Inc. is a clinical-stage biotechnology company
developing innovative therapeutics targeting hepatitis B virus
(HBV) and diseases associated with the microbiome. The HBV program
is focused on advancing a new class of potent, oral core inhibitors
that have the potential to increase cure rates for chronically
infected patients. The microbiome program is developing novel
oral live microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP banking and production, and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology.
Forward-Looking Statements
The information in this press release contains forward-looking
statements regarding future events, including statements about
Assembly’s expectations regarding the terms of the offering or
completion of the offering. Assembly intends such
forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include,
without limitation, risks and uncertainties related to market and
other conditions, the satisfaction of customary closing conditions
related to the offering and the impact of general economic,
industry or political conditions in the United States or
internationally. There can be no assurance that Assembly will be
able to complete the offering on the anticipated terms, or at all.
More information about the risks and uncertainties faced by
Assembly are more fully detailed under the heading “Risk Factors”
in Assembly's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019 filed with the Securities and Exchange
Commission. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this
press release. Except as required by law, Assembly assumes no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts
Investors: Lauren Glaser (415) 521-3828
lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024